… Chemosensitization required apoptosis, and increased the … to explore, in preclinical studies,
therapeutic approaches for … the recurrencefree survival of treated patients to 40%. Tumor …

… Confirming the initial data from patient-derived tumor xenograft (PDX) supported a strong
rationale to repurpose DSF as a radio-chemosensitizer and to assess its therapeutic potential …

… patient tumor histocultures by greater than 2-fold. The chemosensitization effect was observed
in all patient … These encouraging preclinical results led to 4 phase I/II trials using low dose …

… of patients with DLBCL with the routine addition of rituximab therapy, approximately one third
of patients … The fact that the majority of these patients will die within two years of diagnosis …

… clinical features and poor prognosis in NPC patients [11]. Although the … studies are warranted
to explore the best administration sequence to fully utilize this potential chemosensitizing …

… In preclinical studies, the treatment with AS Bcl-2 in combination with an anticancer drug …
for relapsed multiple myeloma patients showed that responding patients had a significant …

… We recently reported that paclitaxel has been difficult to evaluate in pre-clinical … preclinical
data provide support for clinical studies with antisense Bcl-2 ODN plus taxanes for patients …

… Cell line studies support this hypothesis and show chemosensitization and radiosensitization
by … Inhibitors of these kinases are at various stages of preclinical and clinical development. …

… Here, we describe the preclinical evaluation of KU-0060648. … of predictive biomarkers,
which could be used to identify patients sensitive to KU-0060648 as a single-agent therapy. …

… doses) were evaluated in multiple myeloma patients and it was … and feasible in patients
with pancreatic cancer [15]. These … Congregate evidence from in vitro and preclinical studies …